-
1
-
-
33646568784
-
Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world
-
Kamangar F, Dores GM, Anderson W. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24:2137-50
-
(2006)
J Clin Oncol
, vol.24
, pp. 2137-2150
-
-
Kamangar, F.1
Dores, G.M.2
Anderson, W.3
-
2
-
-
0034921235
-
The expanding world of co-stimulation: The two-signal model revisited
-
Chambers CA. The expanding world of co-stimulation: the two-signal model revisited. Trends Immunol 2001;22:217-23
-
(2001)
Trends Immunol
, vol.22
, pp. 217-223
-
-
Chambers, C.A.1
-
3
-
-
0034596948
-
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
-
Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000;192:1027-34
-
(2000)
J Exp Med
, vol.192
, pp. 1027-1034
-
-
Freeman, G.J.1
Long, A.J.2
Iwai, Y.3
-
4
-
-
0026567027
-
The role of cell division in the induction of clonal anergy
-
Jenkins MK. The role of cell division in the induction of clonal anergy. Immunol Today 1992;13:69-73
-
(1992)
Immunol Today
, vol.13
, pp. 69-73
-
-
Jenkins, M.K.1
-
5
-
-
0036170440
-
Activation and inhibition of lymphocytes by costimulation
-
Frauwirth KA, Thompson CB. Activation and inhibition of lymphocytes by costimulation. J Clin Invest 2002;109:295-309
-
(2002)
J Clin Invest
, vol.109
, pp. 295-309
-
-
Frauwirth, K.A.1
Thompson, C.B.2
-
6
-
-
41649102470
-
Influence of CD80 and CD86 co-stimulation in the modulation of the activation of antigen presenting cells
-
Manzoor A Mir, Javed N Agrewala. Influence of CD80 and CD86 co-stimulation in the modulation of the activation of antigen presenting cells. Curr Immunol Rev 2007;3:160-9
-
(2007)
Curr Immunol Rev
, vol.3
, pp. 160-169
-
-
Mir, M.A.1
Agrewala, J.N.2
-
7
-
-
0036852170
-
CTLA-4-Ig regulates tryptophan catabolism in vivo
-
Grohmann U, Orabona C, Fallarino F, et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 2002;3:1097-101
-
(2002)
Nat Immunol
, vol.3
, pp. 1097-1101
-
-
Grohmann, U.1
Orabona, C.2
Fallarino, F.3
-
8
-
-
34748835898
-
IDO and regulatory T cells: A role for reverse signalling and non-canonical NFκB activation [review]
-
Puccetti P, Grohmann U. IDO and regulatory T cells: a role for reverse signalling and non-canonical NFκB activation [review]. Nat Rev Immunol 2007;7:817-23
-
(2007)
Nat Rev Immunol
, vol.7
, pp. 817-823
-
-
Puccetti, P.1
Grohmann, U.2
-
9
-
-
21044458270
-
Cutting edge: Silencing suppressor of cytokine signaling 3 expression in dendritic cells turns CD28-Ig from immune adjuvant to suppressant
-
Orabona C, Belladonna ML, Vacca C, et al. Cutting edge: silencing suppressor of cytokine signaling 3 expression in dendritic cells turns CD28-Ig from immune adjuvant to suppressant. J Immunol 2005;174:6582-6
-
(2005)
J Immunol
, vol.174
, pp. 6582-6586
-
-
Orabona, C.1
Belladonna, M.L.2
Vacca, C.3
-
10
-
-
33645129040
-
Emerging drugs for chronic lymphocytic leukaemia
-
Yee KW, O'Brien SM. Emerging drugs for chronic lymphocytic leukaemia. Expert Opin Emerging Drugs 2006;11:167-89
-
(2006)
Expert Opin Emerging Drugs
, vol.11
, pp. 167-189
-
-
Yee, K.W.1
O'Brien, S.M.2
-
11
-
-
0037040863
-
Distinct role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphoma
-
Suvas S, Singh V, Sahdev S, et al. Distinct role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphoma. J Biol Chem 2002;277:7766-75
-
(2002)
J Biol Chem
, vol.277
, pp. 7766-7775
-
-
Suvas, S.1
Singh, V.2
Sahdev, S.3
-
12
-
-
0029896194
-
Transmembrane signaling through CD80 B7-1 induces growth arrest and cell spreading of human B lymphocytes accompanied by protein tyrosine phosphorylation
-
Hirokawa M, Kuroki J, Kitabayashi A, Miura AB. Transmembrane signaling through CD80 B7-1 induces growth arrest and cell spreading of human B lymphocytes accompanied by protein tyrosine phosphorylation. Immunol Lett 1996;50:95-8
-
(1996)
Immunol Lett
, vol.50
, pp. 95-98
-
-
Hirokawa, M.1
Kuroki, J.2
Kitabayashi, A.3
Miura, A.B.4
-
13
-
-
22344436992
-
Phase I/II study of galiximab, an antt-CD80 antibody, for relapsed or refractory follicular lymphoma
-
Czuczman MS, Thall A, Witzig TE, et al. Phase I/II study of galiximab, an antt-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol 2005;23:4390-8
-
(2005)
J Clin Oncol
, vol.23
, pp. 4390-4398
-
-
Czuczman, M.S.1
Thall, A.2
Witzig, T.E.3
-
14
-
-
34547844167
-
-
Leonard J, Friedberg J, Younes A, et al. A phase I/II study of galiximab an anti-CD80 monoclonal antibody in combination with rituximab for relapsed or refractory, follicular lymphoma. Ann Oncol 2007;29. Ann Oncol 2007;18:1216-23
-
Leonard J, Friedberg J, Younes A, et al. A phase I/II study of galiximab an anti-CD80 monoclonal antibody in combination with rituximab for relapsed or refractory, follicular lymphoma. Ann Oncol 2007;29. Ann Oncol 2007;18:1216-23
-
-
-
-
15
-
-
2942674463
-
Co-signaling molecules of the B7-CD28 family in positive and negative regulation of T lymphocyte responses
-
Wang S, Chen L. Co-signaling molecules of the B7-CD28 family in positive and negative regulation of T lymphocyte responses. Microbes Infect 2004;6:759-66
-
(2004)
Microbes Infect
, vol.6
, pp. 759-766
-
-
Wang, S.1
Chen, L.2
-
16
-
-
0033565764
-
Two mechanisms for tumor evasion of preexisting cytotoxic T-cell responses: Lessons from recurrent tumors
-
Zheng P, Sarma S, Guo Y, Liu Y. Two mechanisms for tumor evasion of preexisting cytotoxic T-cell responses: lessons from recurrent tumors. Cancer Res 1999;59:3461-7
-
(1999)
Cancer Res
, vol.59
, pp. 3461-3467
-
-
Zheng, P.1
Sarma, S.2
Guo, Y.3
Liu, Y.4
-
17
-
-
0028952046
-
Role of B7-1 in mediating an immune response to myeloid leukemia cells
-
Matulonis UA, Dosiou C, Lamont C, et al. Role of B7-1 in mediating an immune response to myeloid leukemia cells. Blood 1995;85:2507-15
-
(1995)
Blood
, vol.85
, pp. 2507-2515
-
-
Matulonis, U.A.1
Dosiou, C.2
Lamont, C.3
-
18
-
-
0028343870
-
T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: An important role of B7/ BB1 in the induction, recruitment, and effector function of antitumor T cells
-
Ramarathinam L, Castle M, WU Y, Liu Y. T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/ BB1 in the induction, recruitment, and effector function of antitumor T cells. J Exp Med 1994;179:1205-14
-
(1994)
J Exp Med
, vol.179
, pp. 1205-1214
-
-
Ramarathinam, L.1
Castle, M.2
WU, Y.3
Liu, Y.4
-
19
-
-
0029864363
-
Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo?
-
Huang AY, Bruce AT, Pardoll DM, Levitsky HI. Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J Exp Med 1996;183:769-76
-
(1996)
J Exp Med
, vol.183
, pp. 769-776
-
-
Huang, A.Y.1
Bruce, A.T.2
Pardoll, D.M.3
Levitsky, H.I.4
-
20
-
-
0028861977
-
A reassessment of the role of B7-1 expression in tumor rejection
-
WU TC, Huang AY, Jaffee EM, et al. A reassessment of the role of B7-1 expression in tumor rejection. J Exp Med 1995;182:1415-21
-
(1995)
J Exp Med
, vol.182
, pp. 1415-1421
-
-
WU, T.C.1
Huang, A.Y.2
Jaffee, E.M.3
-
21
-
-
33747803052
-
CD8+ cytotoxic T-APC stimulate central memory CD8+ T cell responses via acquired peptide-MHC class I complexes and CD80 costimulation, and IL-2 secretion
-
Xia D, Hao S, Xiang J. CD8+ cytotoxic T-APC stimulate central memory CD8+ T cell responses via acquired peptide-MHC class I complexes and CD80 costimulation, and IL-2 secretion. J Immunol 2006;177:2976-84
-
(2006)
J Immunol
, vol.177
, pp. 2976-2984
-
-
Xia, D.1
Hao, S.2
Xiang, J.3
-
22
-
-
0035889949
-
Role of CD28-B7 interactions in generation and maintenance of CD8 T cell memory
-
Suresh M, Whitmire JK, Harrington LE, et al. Role of CD28-B7 interactions in generation and maintenance of CD8 T cell memory. J Immunol 2001;167:5565-73
-
(2001)
J Immunol
, vol.167
, pp. 5565-5573
-
-
Suresh, M.1
Whitmire, J.K.2
Harrington, L.E.3
-
23
-
-
0033384806
-
The role of T cell costimulation by CD80 in the initiation and maintenance of the immune response to human leukemia
-
Matsumoto K, Anasetti C. The role of T cell costimulation by CD80 in the initiation and maintenance of the immune response to human leukemia. Leuk Lymphoma 1999;35:427-35
-
(1999)
Leuk Lymphoma
, vol.35
, pp. 427-435
-
-
Matsumoto, K.1
Anasetti, C.2
-
24
-
-
0030026868
-
B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro
-
Gajewski TF. B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro. J Immunol 1996;156:465-72
-
(1996)
J Immunol
, vol.156
, pp. 465-472
-
-
Gajewski, T.F.1
-
25
-
-
0032534599
-
Importance of B7-1-expressing host antigen-presenting cells for the eradication of B7-2 transfected P815 tumor cells
-
La Motte RN, Sharpe AH, Bluestone JA, Mokyr MB. Importance of B7-1-expressing host antigen-presenting cells for the eradication of B7-2 transfected P815 tumor cells. J Immunol 1998;161:6552-8
-
(1998)
J Immunol
, vol.161
, pp. 6552-6558
-
-
La Motte, R.N.1
Sharpe, A.H.2
Bluestone, J.A.3
Mokyr, M.B.4
-
26
-
-
0027451433
-
B7 but not intercellular adhesion molecule-1 costimulation prevents the induction of human alloantigen-specific tolerance
-
Boussiotis VA, Freeman GJ, Gray G, et al. B7 but not intercellular adhesion molecule-1 costimulation prevents the induction of human alloantigen-specific tolerance. J Exp Med 1993;178:1753-63
-
(1993)
J Exp Med
, vol.178
, pp. 1753-1763
-
-
Boussiotis, V.A.1
Freeman, G.J.2
Gray, G.3
-
27
-
-
0026543202
-
Murine B7 antigen provides an efficient costimulatory signal for activation of murine T lymphocytes via the T-cell receptor/CD3 complex
-
Reiser H, Freeman GJ, Razi-Wolf Z, et al. Murine B7 antigen provides an efficient costimulatory signal for activation of murine T lymphocytes via the T-cell receptor/CD3 complex. Proc Natl Acad Sci USA 1992;89:271-5
-
(1992)
Proc Natl Acad Sci USA
, vol.89
, pp. 271-275
-
-
Reiser, H.1
Freeman, G.J.2
Razi-Wolf, Z.3
-
28
-
-
0027175221
-
-
Harding FA, Allison JP CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help. J Exp Med 1993;177:1791-6
-
Harding FA, Allison JP CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help. J Exp Med 1993;177:1791-6
-
-
-
-
30
-
-
0027392843
-
Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells
-
Townsend SE, Allison JP. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 1993;259:368-70
-
(1993)
Science
, vol.259
, pp. 368-370
-
-
Townsend, S.E.1
Allison, J.P.2
-
31
-
-
33644520242
-
Low surface expression of B7-1 CD80 is an immunoescape mechanism of colon carcinoma
-
Tirapu I, Huarte E, Guiducci C, et al. Low surface expression of B7-1 CD80 is an immunoescape mechanism of colon carcinoma. Cancer Res 2006;66:2442-50
-
(2006)
Cancer Res
, vol.66
, pp. 2442-2450
-
-
Tirapu, I.1
Huarte, E.2
Guiducci, C.3
-
32
-
-
0036569402
-
A role for IFN-γ in primary and secondary immunity generated by NK cell-sensitive tumor-expressing CD80 in vivo
-
Kelly JM, Takeda K, Darcy PK, et al. A role for IFN-γ in primary and secondary immunity generated by NK cell-sensitive tumor-expressing CD80 in vivo. J Immunol 2002;168:4472-9
-
(2002)
J Immunol
, vol.168
, pp. 4472-4479
-
-
Kelly, J.M.1
Takeda, K.2
Darcy, P.K.3
-
33
-
-
0030273745
-
Triggering of natural killer cells by the costimulatory molecule CD80 B7-1
-
Chambers BJ, Salcedo M, Ljunggren HG. Triggering of natural killer cells by the costimulatory molecule CD80 B7-1. Immunity 1996;5:311-7
-
(1996)
Immunity
, vol.5
, pp. 311-317
-
-
Chambers, B.J.1
Salcedo, M.2
Ljunggren, H.G.3
-
34
-
-
0344737668
-
Two-signal requirement for activation and effector function of natural killer cell response to allogeneic tumor cells
-
Gao JX, Liu X, Wen J, et al. Two-signal requirement for activation and effector function of natural killer cell response to allogeneic tumor cells. Blood 2003;102:4456-63
-
(2003)
Blood
, vol.102
, pp. 4456-4463
-
-
Gao, J.X.1
Liu, X.2
Wen, J.3
-
36
-
-
0029070142
-
Expression of B7-1 by highly metastatic mouse T lymphomas induces optimal natural killer cell-mediated cytotoxicity
-
Geldhof AB, Raes G, Bakkus M, et al. Expression of B7-1 by highly metastatic mouse T lymphomas induces optimal natural killer cell-mediated cytotoxicity. Cancer Res 1995;55:2730-3
-
(1995)
Cancer Res
, vol.55
, pp. 2730-2733
-
-
Geldhof, A.B.1
Raes, G.2
Bakkus, M.3
-
37
-
-
0027078670
-
Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4
-
Chen L, Ashe S, Brady WA, et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992;71:1093-102
-
(1992)
Cell
, vol.71
, pp. 1093-1102
-
-
Chen, L.1
Ashe, S.2
Brady, W.A.3
-
38
-
-
0027211058
-
Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules
-
Baskar S, Ostrand-Rosenberg S, Nabavi N, et al. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc Natl Acad Sci USA 1993;90:5687-90
-
(1993)
Proc Natl Acad Sci USA
, vol.90
, pp. 5687-5690
-
-
Baskar, S.1
Ostrand-Rosenberg, S.2
Nabavi, N.3
-
39
-
-
7444229121
-
Usefulness of inhibiting the lymph node metastasis in human gastric carcinoma by B71 gene transfection
-
Sakate Y, Yashiro M, Tanaka H, et al. Usefulness of inhibiting the lymph node metastasis in human gastric carcinoma by B71 gene transfection. J Surg Res 2004;122:89-95
-
(2004)
J Surg Res
, vol.122
, pp. 89-95
-
-
Sakate, Y.1
Yashiro, M.2
Tanaka, H.3
-
40
-
-
0031839501
-
The role of B7-CD28 co-stimulation in tumor rejection
-
Yu X, Abe R, Hodes RJ. The role of B7-CD28 co-stimulation in tumor rejection. Int Immunol 1998;10:791-7
-
(1998)
Int Immunol
, vol.10
, pp. 791-797
-
-
Yu, X.1
Abe, R.2
Hodes, R.J.3
-
41
-
-
0037089410
-
B7-CTLA4 interaction promotes cognate destruction of tumor cells by cytotoxic T lymphocytes in vivo
-
Bai XF, Liu J, May KF Jr, et al. B7-CTLA4 interaction promotes cognate destruction of tumor cells by cytotoxic T lymphocytes in vivo. Blood 2002;99:2880-9
-
(2002)
Blood
, vol.99
, pp. 2880-2889
-
-
Bai, X.F.1
Liu, J.2
May Jr, K.F.3
-
42
-
-
0028223557
-
T-helper- and accessory-cell-independent cytotoxic responses to human tumor cells transfected with a B7 retroviral vector
-
Dohring C, Angman L, Spagnoli G, Lanzavecchia A. T-helper- and accessory-cell-independent cytotoxic responses to human tumor cells transfected with a B7 retroviral vector. Int J Cancer 1994;57:754-9
-
(1994)
Int J Cancer
, vol.57
, pp. 754-759
-
-
Dohring, C.1
Angman, L.2
Spagnoli, G.3
Lanzavecchia, A.4
-
43
-
-
0028853546
-
A B7-1-transfected human melanoma line stimulates proliferation and cytotoxicity of autologous and allogeneic lymphocytes
-
Sule-Suso J, Arienti F, Melani C, et al. A B7-1-transfected human melanoma line stimulates proliferation and cytotoxicity of autologous and allogeneic lymphocytes. Eur J Immunol 1995;25:2737-42
-
(1995)
Eur J Immunol
, vol.25
, pp. 2737-2742
-
-
Sule-Suso, J.1
Arienti, F.2
Melani, C.3
-
44
-
-
0033682056
-
+ immunoregulatory T cells that control autoimmune diabetes
-
+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000; 12:431-40
-
(2000)
Immunity
, vol.12
, pp. 431-440
-
-
Salomon, B.1
Lenschow, D.J.2
Rhee, L.3
-
45
-
-
0034660469
-
Melphalan and other anticancer modalities up-regulate B7-1 gene expression in tumor cells
-
Sojka DK, Donepudi M, Bluestone JA, Mokyr MB. Melphalan and other anticancer modalities up-regulate B7-1 gene expression in tumor cells. J Immunol 2000;164:6230-6
-
(2000)
J Immunol
, vol.164
, pp. 6230-6236
-
-
Sojka, D.K.1
Donepudi, M.2
Bluestone, J.A.3
Mokyr, M.B.4
-
46
-
-
0037810672
-
The inhibitory function of B7 costimulators in T cell responses to foreign and self-antigens
-
Lohr J, Knoechel B, Jiang S, et al. The inhibitory function of B7 costimulators in T cell responses to foreign and self-antigens. Nat Immunol 2003;4:664-9
-
(2003)
Nat Immunol
, vol.4
, pp. 664-669
-
-
Lohr, J.1
Knoechel, B.2
Jiang, S.3
-
47
-
-
14944375827
-
Dendritic cells giveth and taketh away
-
Abbas AK, Sharpe AH. Dendritic cells giveth and taketh away. Nat Immunol 2005;6:227-8
-
(2005)
Nat Immunol
, vol.6
, pp. 227-228
-
-
Abbas, A.K.1
Sharpe, A.H.2
-
48
-
-
33645450748
-
Primary tumor cells resected from cancer patients and decorated with a novel form of CD80 protein serve as effective antigen-presenting cells for the induction of autologous T cell immune responses ex vivo
-
Singh NP, Miller RW, Yolcu ES, et al. Primary tumor cells resected from cancer patients and decorated with a novel form of CD80 protein serve as effective antigen-presenting cells for the induction of autologous T cell immune responses ex vivo. Hum Gene Ther 2006;17:334-46
-
(2006)
Hum Gene Ther
, vol.17
, pp. 334-346
-
-
Singh, N.P.1
Miller, R.W.2
Yolcu, E.S.3
-
49
-
-
33748880457
-
The mechanism of exogenous B7.1-enhanced IL-12-mediated complete regression of tumors by a single electroporation delivery
-
Liu J, Xia X, Torrero M, et al. The mechanism of exogenous B7.1-enhanced IL-12-mediated complete regression of tumors by a single electroporation delivery. Int J Cancer 2006;119:2113-8
-
(2006)
Int J Cancer
, vol.119
, pp. 2113-2118
-
-
Liu, J.1
Xia, X.2
Torrero, M.3
-
50
-
-
0036230069
-
Improved treatment of pancreatic cancer by IL-12 and B7.1 costimulation: Antitumor efficacy and immunoregulation in a nonimmunogenic tumor model
-
Putzer BM, Rodicker F, Hitt MM, et al. Improved treatment of pancreatic cancer by IL-12 and B7.1 costimulation: antitumor efficacy and immunoregulation in a nonimmunogenic tumor model. Mol Ther 2002;5:405-12
-
(2002)
Mol Ther
, vol.5
, pp. 405-412
-
-
Putzer, B.M.1
Rodicker, F.2
Hitt, M.M.3
-
51
-
-
0029101821
-
Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines
-
Cayeux S, Beck C, Aicher A, et al. Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines. Eur J Immunol 1995;25:2325-31
-
(1995)
Eur J Immunol
, vol.25
, pp. 2325-2331
-
-
Cayeux, S.1
Beck, C.2
Aicher, A.3
-
52
-
-
33745740342
-
Tumor cells with B7.1 and transmembrane anchored staphylococcal enterotoxin A generate effective antitumor immunity
-
Si SY, Hu PZ, Huang YY, et al. Tumor cells with B7.1 and transmembrane anchored staphylococcal enterotoxin A generate effective antitumor immunity. Biochem Biophys Res Commun 2006;347:208-14
-
(2006)
Biochem Biophys Res Commun
, vol.347
, pp. 208-214
-
-
Si, S.Y.1
Hu, P.Z.2
Huang, Y.Y.3
-
53
-
-
0033870234
-
B7-1, IFNγ and anti-CTLA-4 co-operate to prevent T-cell tolerization during immunotherapy against a murine T-lymphoma
-
Van Ginderachter JA, Liu Y, Geldhof AB, et al. B7-1, IFNγ and anti-CTLA-4 co-operate to prevent T-cell tolerization during immunotherapy against a murine T-lymphoma. Int J Cancer 2000;87:539-47
-
(2000)
Int J Cancer
, vol.87
, pp. 539-547
-
-
Van Ginderachter, J.A.1
Liu, Y.2
Geldhof, A.B.3
-
54
-
-
0028898598
-
Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice
-
Baskar S, Glimcher L, Nabavi N, et al. Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J Exp Med 1995;181:619-29
-
(1995)
J Exp Med
, vol.181
, pp. 619-629
-
-
Baskar, S.1
Glimcher, L.2
Nabavi, N.3
-
55
-
-
0037259316
-
Transfection of B7-1 cDNA empowers antigen presentation of blood malignant cells for activation of anti-tumor T cells
-
Ke X, Jia L, Wang J, Wang D. Transfection of B7-1 cDNA empowers antigen presentation of blood malignant cells for activation of anti-tumor T cells. Chin Med J Engl 2003;116:78-84
-
(2003)
Chin Med J Engl
, vol.116
, pp. 78-84
-
-
Ke, X.1
Jia, L.2
Wang, J.3
Wang, D.4
-
56
-
-
10944238100
-
IL-2/B7.1 CD80 fusagene transduction of AML blasts by a self-inactivating lentiviral vector stimulates T cell responses in vitro: A strategy to generate whole cell vaccines for AML
-
Chan L, Hardwick N, Darling D, et al. IL-2/B7.1 CD80 fusagene transduction of AML blasts by a self-inactivating lentiviral vector stimulates T cell responses in vitro: a strategy to generate whole cell vaccines for AML. Mol Ther 2005;11:120-31
-
(2005)
Mol Ther
, vol.11
, pp. 120-131
-
-
Chan, L.1
Hardwick, N.2
Darling, D.3
-
57
-
-
0036223749
-
Phase I trial of a B7-1 CD80 gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma
-
Antonia Sj, Seigne J, Diaz J, et al. Phase I trial of a B7-1 CD80 gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. J Urol 2002;167:1995-2000
-
(2002)
J Urol
, vol.167
, pp. 1995-2000
-
-
Antonia, S.1
Seigne, J.2
Diaz, J.3
-
58
-
-
0034920504
-
Tricistronic viral vectors co-expressing interleukin-12 (IL-12) and CD80 (B7-1) for the immunotherapy of cancer: Preclinical studies in myeloma
-
Wen XY, Mandelbaum S, Li ZH, et al. Tricistronic viral vectors co-expressing interleukin-12 (IL-12) and CD80 (B7-1) for the immunotherapy of cancer: preclinical studies in myeloma. Cancer Gene Ther 2001;8:361-70
-
(2001)
Cancer Gene Ther
, vol.8
, pp. 361-370
-
-
Wen, X.Y.1
Mandelbaum, S.2
Li, Z.H.3
-
59
-
-
0037616155
-
Apoptotic cell death in conjunction with CD80 costimulation confers uveal melanoma cells with the ability to induce immune responses
-
Carlring J, Shaif-Muthana M, Sisley K, et al. Apoptotic cell death in conjunction with CD80 costimulation confers uveal melanoma cells with the ability to induce immune responses. Immunology 2003;109:41-8
-
(2003)
Immunology
, vol.109
, pp. 41-48
-
-
Carlring, J.1
Shaif-Muthana, M.2
Sisley, K.3
-
60
-
-
0036320834
-
Activation of caspase-3 alone is insufficient for apoptotic morphological changes in human neuroblastoma cells
-
Racke Mm, Mosior M, Kovacevic S. Activation of caspase-3 alone is insufficient for apoptotic morphological changes in human neuroblastoma cells. J Neurochem 2002;80:1039-48
-
(2002)
J Neurochem
, vol.80
, pp. 1039-1048
-
-
Racke, M.1
Mosior, M.2
Kovacevic, S.3
-
61
-
-
0034667357
-
Interferon-γ treatment elevates caspase-8 expression and sensitizes human breast tumor cells to a death receptor-induced mitochondria-operated apoptotic program
-
Ruiz-Ruiz C, Munoz-Pinedo C, Lopez-Rivas A. Interferon-γ treatment elevates caspase-8 expression and sensitizes human breast tumor cells to a death receptor-induced mitochondria-operated apoptotic program. Cancer Res 2000;60:5673-80
-
(2000)
Cancer Res
, vol.60
, pp. 5673-5680
-
-
Ruiz-Ruiz, C.1
Munoz-Pinedo, C.2
Lopez-Rivas, A.3
-
62
-
-
0028791059
-
Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4
-
Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995;270:985-8
-
(1995)
Science
, vol.270
, pp. 985-988
-
-
Waterhouse, P.1
Penninger, J.M.2
Timms, E.3
-
63
-
-
33747821753
-
Cyclin E but not bcl-2, bax or mcl-1 is differentially expressed in ZAP 70-positive and ZAP 70-negative B-CLL cells
-
Bogner C, Sandherr M, Perker M, et al. Cyclin E but not bcl-2, bax or mcl-1 is differentially expressed in ZAP 70-positive and ZAP 70-negative B-CLL cells. Ann Hematol 2006;85:458-62
-
(2006)
Ann Hematol
, vol.85
, pp. 458-462
-
-
Bogner, C.1
Sandherr, M.2
Perker, M.3
-
64
-
-
9244247370
-
CD28-B7 bidirectional signaling: A two-way street to activation
-
Logue EC, Sha WC. CD28-B7 bidirectional signaling: a two-way street to activation. Nat Immunol 2004;5:1103-5
-
(2004)
Nat Immunol
, vol.5
, pp. 1103-1105
-
-
Logue, E.C.1
Sha, W.C.2
-
65
-
-
9244231842
-
CD28 induces immuno-stimulatory signals in dendritic cells via CD80 and CD86
-
Orabona C, Grohmann U, Belladonna ML, et al. CD28 induces immuno-stimulatory signals in dendritic cells via CD80 and CD86. Nat Immunol 2004;5:1134-42
-
(2004)
Nat Immunol
, vol.5
, pp. 1134-1142
-
-
Orabona, C.1
Grohmann, U.2
Belladonna, M.L.3
-
66
-
-
2142714017
-
Monoclonal antibodies as therapeutic agents for cancer [review]
-
Harris M. Monoclonal antibodies as therapeutic agents for cancer [review]. Lancet Oncol 2004;5(5):292-302
-
(2004)
Lancet Oncol
, vol.5
, Issue.5
, pp. 292-302
-
-
Harris, M.1
-
67
-
-
0037092951
-
Therapeutic role of alemtuzumab (campath H1) in patients who have failed fludarabine: Results of a large international study
-
Keating M, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (campath H1) in patients who have failed fludarabine: results of a large international study. Blood 2002;99:3554-61
-
(2002)
Blood
, vol.99
, pp. 3554-3561
-
-
Keating, M.1
Flinn, I.2
Jain, V.3
-
68
-
-
0043177668
-
Bevacizumab a monoclonal antibody to vascular-endothelial growth factor prolongs survival in first-line colorectal cancer: Results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5 fluorouracil, leucovorin) as first-line therapy in subjects with metastatic colorectal cancer [abstract 3646]
-
Hurwitz H, Fehrenbacher L, Cartwright T, et al. Bevacizumab a monoclonal antibody to vascular-endothelial growth factor prolongs survival in first-line colorectal cancer: results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5 fluorouracil, leucovorin) as first-line therapy in subjects with metastatic colorectal cancer [abstract 3646]. Proc Am Soc Clin Oncol 2003;22
-
(2003)
Proc Am Soc Clin Oncol
, pp. 22
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Cartwright, T.3
-
69
-
-
0037251878
-
Rituximab: A review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia [review]
-
Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia [review]. Drugs 2003;63:803-43
-
(2003)
Drugs
, vol.63
, pp. 803-843
-
-
Plosker, G.L.1
Figgitt, D.P.2
-
70
-
-
0030800131
-
Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs
-
Demidem A, Lam T, Alas S, et al. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997;12:177-85
-
(1997)
Cancer Biother Radiopharm
, vol.12
, pp. 177-185
-
-
Demidem, A.1
Lam, T.2
Alas, S.3
-
71
-
-
0033855660
-
Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment
-
Davis TA, Grillo-López AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000;18:3135-43
-
(2000)
J Clin Oncol
, vol.18
, pp. 3135-3143
-
-
Davis, T.A.1
Grillo-López, A.J.2
White, C.A.3
-
72
-
-
48449095747
-
-
IDEC Pharmaceuticals. Rituxan (rituximab) package insert. San Diego, CA, IDEC Pharmaceuticals Corporation; 2002
-
IDEC Pharmaceuticals. Rituxan (rituximab) package insert. San Diego, CA, IDEC Pharmaceuticals Corporation; 2002
-
-
-
-
73
-
-
0345604387
-
Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma
-
Lyman GH, Delgado DJ. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer 2003;98:2402-9
-
(2003)
Cancer
, vol.98
, pp. 2402-2409
-
-
Lyman, G.H.1
Delgado, D.J.2
-
74
-
-
48449083215
-
-
Genentech, Inc. Herceptin (trastuzumab) package insert. South San Francisco, CA, Genentech, Inc, 2003
-
Genentech, Inc. Herceptin (trastuzumab) package insert. South San Francisco, CA, Genentech, Inc.; 2003
-
-
-
-
75
-
-
0028568292
-
Immunoglobulin fold characteristics of B7-1 CD80 and B7-2 CD86
-
Bajorath J, Peach RJ, Linsley PS. Immunoglobulin fold characteristics of B7-1 CD80 and B7-2 CD86. Protein Sci 1994;3:2148-50
-
(1994)
Protein Sci
, vol.3
, pp. 2148-2150
-
-
Bajorath, J.1
Peach, R.J.2
Linsley, P.S.3
-
76
-
-
1642295729
-
Novel therapies for chronic lymphocytic leukemia
-
Mavromatis BH, Cheson BD. Novel therapies for chronic lymphocytic leukemia. Blood Rev 2004;18:137-48
-
(2004)
Blood Rev
, vol.18
, pp. 137-148
-
-
Mavromatis, B.H.1
Cheson, B.D.2
-
77
-
-
48449092834
-
Anti-CD80 monoclonal antibody: Galiximab
-
Czuczman MS. Anti-CD80 monoclonal antibody: galiximab. Haematol Rep 2005;36:35-6
-
(2005)
Haematol Rep
, vol.36
, pp. 35-36
-
-
Czuczman, M.S.1
-
78
-
-
1842735276
-
Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis
-
Gottlieb AB, Kang S, Linden KG, et al. Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis. Clin Immunol 2004;111:28-37
-
(2004)
Clin Immunol
, vol.111
, pp. 28-37
-
-
Gottlieb, A.B.1
Kang, S.2
Linden, K.G.3
-
79
-
-
58149271489
-
Combining galiximab with the chemotherapeutic agents fludarabine or doxorubicin improves efficacy in animal models of lymphoma
-
Hariharan HK, Murphy T, Clanton D, et al. Combining galiximab with the chemotherapeutic agents fludarabine or doxorubicin improves efficacy in animal models of lymphoma. ASCO Annual Meeting Proceedings. J Clin Oncol 2007;3:3040
-
(2007)
ASCO Annual Meeting Proceedings. J Clin Oncol
, vol.3
, pp. 3040
-
-
Hariharan, H.K.1
Murphy, T.2
Clanton, D.3
-
80
-
-
7044255364
-
Phase I results from a multicenter trial of galiximab (anti-CD80 antibody, IDEC-114) in combination with rituximab for the treatment of follicular lymphoma [abstract 4951]
-
Gordon LI, Moore JO, Cheson BD, et al. Phase I results from a multicenter trial of galiximab (anti-CD80 antibody, IDEC-114) in combination with rituximab for the treatment of follicular lymphoma [abstract 4951]. Blood 2003;102:307b
-
(2003)
Blood
, vol.102
-
-
Gordon, L.I.1
Moore, J.O.2
Cheson, B.D.3
|